Over the last 12 months, one Traws Pharma, Inc. executives and directors bought shares with their own money, about $998,000 in total, and none of them sold.
OrbiMed Capital GP VIII LLC (10% Owner) made the biggest buy, worth around $998,000.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters. 34 investment managers listed TRAW in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | OrbiMed Capital GP VIII LLC | 10% Owner | Buy | 597,729 | $1.67 | $998K | SEC |
In the last 12 months Traws Pharma, Inc. insiders made open-market purchases worth about $998,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in TRAW was filed on 2026-04-28.
34 investment managers reported holding TRAW in SEC Form 13F filings for Q2 2026.
No congressional trades in TRAW were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).